HealthEquity (HQY) Stock Looks Undervalued On Its 49% Five Year Run

HealthEquity shares have delivered a 48.9% gain over the past 5 years, which puts a lot of weight on whether the current price around US$97.88 is fully backed by the cash the business is expected to generate. With that kind of longer term return already on the table, the key issue now is how those cash flows compare with what investors are paying today.

• Over 5 years the stock is up 48.9%, which raises the question of how much future cash generation is already reflected in the share price.
• The business model relies heavily on converting health savings account activity into recurring fees and cash. This can shape both the level and timing of cash flows that feed into intrinsic value estimates.
• If you'd rather focus on earnings, this one's for you. See why HealthEquity's 34.2x P/E tells a different valuation story.

The issue now is whether the stock price around US$97.88 is justified by HealthEquity's cash flows when tested against a Discounted Cash Flow (DCF) intrinsic value estimate.

If you are evaluating HealthEquity based on its cash flows, it may also be useful to compare it with a broader group of companies that meet clear valuation criteria through 33 high quality undervalued stocks.

Does HealthEquity Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) approach values HealthEquity based on the cash it can return to shareholders over time. Over the latest twelve months, the business generated roughly $266.3m of free cash flow, and the model assumes that this figure continues to grow rather than shrink as the health savings account platform scales.

Analysts contributing to the DCF expect free cash flow to reach the mid $500m range by the 2029 financial year, then to rise at progressively slower rates as HealthEquity matures. When those projected cash flows are discounted back and compared with the current share price of $97.88, the DCF output indicates that HealthEquity's estimated intrinsic value is substantially above the current share price. Find out what HealthEquity could be worth using our Discounted Cash Flow (DCF) estimate.

The HealthEquity Narrative: What Would Justify Today's Price?

Narratives pick up where the DCF puzzle leaves off. For HealthEquity, they spell out which paths for growth, margins and earnings would need to play out for the valuation to sit meaningfully above or below today's price. They sit on Simply Wall St's Community page so you can see each scenario's underlying fair value assumptions and then line those up against actual results as quarterly numbers arrive.

One of the top community narratives on HealthEquity: 18% undervalued

"AI driven automation that has already reduced human handled calls by 25% and materially lowered fraud losses is still rolling through service..."

Discover why this Narrative puts HealthEquity at 18% undervalued.

HealthEquity’s price is only one piece of the decision

Before you put a final view on HealthEquity, it is worth asking how the people directing capital are selected, rewarded and aligned with your interests, because that answer can heavily shape long term outcomes. See who runs HealthEquity and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com